Pfizer Forgoes Fees To Close Accupril Suit

Law360, New York (July 9, 2008, 12:00 AM EDT) -- A Pfizer Inc. subsidiary has ended its decade-old dispute with Teva Pharmaceuticals USA Inc. over the hypertension drug Accupril by dropping attorneys' fees and willful infringement claims in exchange for Teva dropping its appeal of a finding that the generics maker infringed Pfizer's patent.

Judge Dickinson R. Debevoise of the U.S. District Court for the District of New Jersey dismissed the case with prejudice Monday after Warner-Lambert Co. and Teva inked agreements last month dropping the appeal and the additional claims, which were bifurcated from the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.